NASDAQ:KMDA - Kamada Stock Price, Forecast & News

Kamada's stock was trading at $5.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KMDA shares have increased by 6.6% and is now trading at $5.49. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kamada.

Kamada is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Kamada.

Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings data on Wednesday, February, 12th. The biotechnology company reported $0.13 earnings per share for the quarter, meeting analysts' consensus estimates of $0.13. The biotechnology company had revenue of $32.07 million for the quarter, compared to the consensus estimate of $31.63 million. Kamada had a return on equity of 17.56% and a net margin of 17.50%. View Kamada's earnings history.

Kamada updated its FY 2020 Pre-Market earnings guidance on Wednesday, February, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $132-137 million, compared to the consensus revenue estimate of $135.67 million.

2 analysts have issued twelve-month price objectives for Kamada's stock. Their forecasts range from $7.00 to $11.00. On average, they anticipate Kamada's share price to reach $9.00 in the next year. This suggests a possible upside of 63.9% from the stock's current price. View analysts' price targets for Kamada.

Media coverage about KMDA stock has been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kamada earned a news impact score of -4.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutKamada.

Kamada saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 30,000 shares, an increase of 581.8% from the February 27th total of 4,400 shares. Based on an average trading volume of 127,400 shares, the short-interest ratio is presently 0.2 days. Currently, 0.1% of the company's stock are short sold. View Kamada's Current Options Chain.

Some companies that are related to Kamada include Akebia Therapeutics (AKBA), Opko Health (OPK), Aimmune Therapeutics (AIMT), Odonate Therapeutics (ODT), Y-mAbs Therapeutics (YMAB), Revance Therapeutics (RVNC), Intra-Cellular Therapies (ITCI), Endo International (ENDP), Supernus Pharmaceuticals (SUPN), Rocket Pharmaceuticals (RCKT), Phathom Pharmaceuticals (PHAT), Phibro Animal Health (PAHC), CannTrust (CNTTF), Homology Medicines (FIXX) and Kiniksa Pharmaceuticals (KNSA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Zoetis (ZTS) and Micron Technology (MU).

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Kamada's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.11%), Norges Bank (0.90%), Marshall Wace LLP (0.19%), ARK Investment Management LLC (0.17%), UBS Group AG (0.15%) and Jane Street Group LLC (0.13%).

KMDA stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC.

KMDA stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Renaissance Technologies LLC, UBS Group AG, Marshall Wace LLP, Seizert Capital Partners LLC, and Jane Street Group LLC.

Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KMDA stock can currently be purchased for approximately $5.49.

Kamada has a market capitalization of $244.41 million and generates $127.19 million in revenue each year. The biotechnology company earns $22.25 million in net income (profit) each year or $0.55 on an earnings per share basis. Kamada employs 408 workers across the globe. View additional information about Kamada.

The official website for Kamada is http://www.kamada.com/.

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]